Stromal Palladin as a Prognostic Marker in Renal Cell Carcinoma
Author Information
Author(s): Gupta Vivekanand, Bassi Daniel E., Simons Jeffrey D., Devarajan Karthik, Al-Saleem Tahseen, Uzzo Robert G., Cukierman Edna
Primary Institution: Fox Chase Cancer Center
Hypothesis
The study aims to determine the predictive value of stromal markers on patient survival in renal cell carcinoma (RCC).
Conclusion
High levels of stromal palladin in RCC are associated with poor patient prognosis.
Supporting Evidence
- Patients with low stromal palladin levels had significantly higher survival rates.
- Stromal palladin expression was correlated with overall survival in non-metastatic RCC patients.
- 3D cultures accurately represented the tumor-associated stromal compartment.
Takeaway
This study found that a protein called palladin in the tissue around kidney tumors can help predict how well patients will do.
Methodology
The study analyzed stromal marker expression in a tumor microarray and used a 3D culture system to evaluate fibroblast behavior.
Potential Biases
Potential bias in scoring by pathologists and limited survival data for some patients.
Limitations
The study's findings are based on a limited number of samples and may not be generalizable to all RCC cases.
Participant Demographics
The cohort included 53 RCC samples, with 62% being clear cell carcinomas; 35% female and 65% male.
Statistical Information
P-Value
p=0.004 for node positive vs. node negative; p=0.001 for metastatic vs. non-metastatic; p=0.014 for palladin levels.
Confidence Interval
(0.36, 0.73)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website